Skip to content

A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults

A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02704208
Acronym
TWM
Enrollment
410
Registered
2016-03-09
Start date
2016-10-01
Completion date
2022-05-31
Last updated
2023-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Keywords

Antiretroviral Therapy, Medication Adherence, Technology-based Intervention

Brief summary

The Thrive With Me (TWM) trial is testing the efficacy of a mobile enhanced website aimed at improving Antiretroviral Therapy (ART) adherence for HIV-positive men who have sex with men (MSM). TWM is a technology-delivered peer-to-peer social support intervention with social networking and gaming components. In addition to real-time peer-to-peer support capabilities, the TWM intervention provides participants with Antiretroviral Therapy (ART) adherence self-monitoring tools, medication dose reminders, and HIV-related informational content.

Detailed description

The Thrive with Me (TWM) intervention is a technology-delivered peer-to-peer social support intervention grounded in the Information, Motivation, and Behavioral Skills (IMB) model for HIV positive men who have sex with men (MSM). In addition to asynchronous peer-to-peer support capabilities, the TWM intervention provides participants with Antiretroviral Therapy (ART) adherence self-monitoring tools, medication dose reminders, and HIV-related informational content. Based on the encouraging findings of the TWM pilot study (completed in 2011) and the need for novel, evidence-based effective ART adherence interventions, we propose the following study aims for this full-scale RCT. Primary aims (Aims 1 and 2) are to examine the efficacy of the online and mobile-enabled TWM intervention in a full-scale randomized controlled trial. HIVpositive adults (all men who have sex with men \[MSM\]) with detectable HIV viral load (VL) residing in New York City will be randomized to receive the TWM intervention or an information-only HIV/ART intervention for a 6-month period. Recruitment will be stratified by recent drug use, such that half will report recent illicit drug use. HIV VL, validated self-reported ART adherence, and intervention utilization measures will be collected at baseline, post-intervention, and 6-, and 12- month follow up. We hypothesize that participants in the TWM intervention will demonstrate significant improvements in self-reported ART adherence and VL at each follow-up time point compared to control participants, with greatest improvements among recent drug users. Aim 3 (a secondary aim) is to examine the effects of the intervention on theory-based change processes (i.e., IMB factors and social support) for improving VL, ART adherence, and substance use outcomes. We hypothesize that tailored adherence information, motivation for adherence, adherence behavioral skills, and peer social support will be associated with VL suppression and improved ART adherence and drug use outcomes. All study participants will reside in the New York City metropolitan area. The Center for HIV Education Studies and Training at CUNY Hunter College is overseeing the recruitment, enrollment, and retention of human subjects. The primary outcome measure is biological viral load (VL) at each assessment period. Specifically, blood draws will be taken at baseline, immediate post-intervention, 6- and 12-month post-intervention follow-up assessment points to assess the effects of the TWM intervention on VL, the most important biological marker for adherence. Plasma VL is considered undetectable at \<20 copies/mm3 and we will provide test results to participants after each visit. The University of Minnesota IRB is overseeing all human subjects protocols for the study. Brief Summary The Thrive with Me (TWM) intervention is a technology-delivered peer-to-peer social support intervention grounded in the Information, Motivation, and Behavioral Skills (IMB) model for HIV positive men who have sex with men (MSM). In addition to asynchronous peer-to-peer support capabilities, the TWM intervention provides participants with Antiretroviral Therapy (ART) adherence self-monitoring tools, medication dose reminders, and HIV-related informational content. This is a randomized control efficacy trial of the TWM intervention. The primary outcome measure is biological viral load (VL) at each assessment period. All study participants will reside in the New York City metropolitan area. The Center for HIV Education Studies and Training at CUNY Hunter College is overseeing the recruitment, enrollment, and retention of human subjects.

Interventions

BEHAVIORALThrive With Me Control

Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.

BEHAVIORALThrive With Me Intervention

Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Center for HIV Educational Studies & Training
CollaboratorOTHER
University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. 18+ years of age; 2. Male gender; 3. Sex with 1+ men in the prior year; 4. Diagnosis of HIV and currently prescribed ART; 5. Self-reported detectable VL in past 12 months OR self-reported problems with HIV medication adherence; 6. Residing in the New York City metropolitan area and availability meet with project staff at each assessment time point; and 7. English-speaking (since the intervention will be in English). 8. Self-reported recent drug use (the sample will be stratified by recent drug use and non-recent drug use)

Exclusion criteria

1. 17 years of age or younger; 2. Not male gender; 3. 0 male sex partners in the prior year; 4. No diagnosis of HIV and/or not currently prescribed ART; 5. No self-reported detectable VL in past 12 months OR self- reported very good/excellent HIV medication adherence; 6. Residing outside of the New York City metropolitan area and/or no availability meet with project staff at each assessment time point; and 7. Non-English-speaking (since the intervention will be in English).

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Participants With an Undetectable HIV Viral Loadup to 17 months periodUndetectable viral load (plasma viral load is considered undetectable at \<20 copies/mm3)

Countries

United States

Participant flow

Recruitment details

Men residing in the New York City metro area were recruited by study staff using active (e.g., direct outreach) and passive (e.g., advertising in clinic settings, internet-based) recruitment approaches. Internet-recruitment efforts were using online venues that cater to the study population and field-based recruitment strategies include conduct on-site preliminary screening via tablets at local bars, clubs, and community events.

Participants by arm

ArmCount
Behavioral: Thrive With Me Intervention
Participants randomized to the TWM Intervention gained access to the TWM website for 150 days. The TWM website includes: peer-to-peer support through a private social network and optimized gaming features; daily SMS communication for medication reminders and mood tracking; medication adherence monitoring; and tailored HIV informational content.
202
Behavioral: Control Arm
Participants randomized to the TWM Control group will receive HIV related content through a weekly web link. The web links will be static pages (not interactive) with information aimed at improving overall wellbeing while living with HIV, but not focused on improving ART medication adherence.
199
Total401

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up4237

Baseline characteristics

CharacteristicBehavioral: Thrive With Me InterventionBehavioral: Control ArmTotal
Age, Continuous40.1 years
STANDARD_DEVIATION 10.8
38.1 years
STANDARD_DEVIATION 10.6
39.1 years
STANDARD_DEVIATION 10.8
Ethnicity (NIH/OMB)
Hispanic or Latino
62 Participants46 Participants108 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
140 Participants153 Participants293 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants4 Participants5 Participants
Race (NIH/OMB)
Asian
1 Participants2 Participants3 Participants
Race (NIH/OMB)
Black or African American
123 Participants107 Participants230 Participants
Race (NIH/OMB)
More than one race
12 Participants19 Participants31 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
2 Participants0 Participants2 Participants
Race (NIH/OMB)
Unknown or Not Reported
9 Participants8 Participants17 Participants
Race (NIH/OMB)
White
54 Participants59 Participants113 Participants
Region of Enrollment
United States
202 participants199 participants401 participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
202 Participants199 Participants401 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 2020 / 199
other
Total, other adverse events
2 / 2020 / 199
serious
Total, serious adverse events
0 / 2020 / 199

Outcome results

Primary

Proportion of Participants With an Undetectable HIV Viral Load

Undetectable viral load (plasma viral load is considered undetectable at \<20 copies/mm3)

Time frame: up to 17 months period

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Behavioral: Thrive With Me InterventionProportion of Participants With an Undetectable HIV Viral Load107 Participants
Behavioral: Control ArmProportion of Participants With an Undetectable HIV Viral Load113 Participants

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026